All In Biotech

Drug Trial Radar · NCT06375343

Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®

Phase I Clinical Study to Evaluate the Safety and Tolerability of PRO-240 Ophthalmic Solution Compared to Optive® on the Ocular Surface of Ophthalmologically and Clinically Healthy Volunteers

Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

32

Planned (sponsor's estimate)

Start

Jul 30, 2027

Primary completion

Mar 30, 2028

Study completion Apr 30, 2028

Sponsor

Sponsor type
Industry
First posted
Apr 19, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a phase I clinical study to evaluating safety and tolerability of PRO-240 ophthalmic solution through the incidence of unexpected adverse events, as well as through changes in Best Corrected Visual Acuity (BCVA), and the incidence of stinging after its administration, compared to Optive®.

Conditions

  • Dry Eye Disease
  • Dry Eye Sensation
  • Ocular Surface Disease

Interventions

  • PRO-240Drug

    -Propylene glycol 0.3%, Polyethylene glycol 400 0.5%, and Glycerin 0.2%. Ophthalmic solution.

  • Optive®Drug

    \- Carboxymethylcellulose 0.5%, and Glycerin 0.9%. Ophthalmic solution.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of unexpected adverse events related to the interventionsTime frame: Days 0: (Basal Visit), 8 (Final Visit) and 11 (Safety Call)

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.